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Artificial intelligence can not only mimic but also greatly extend human intelligence. 
Machine learning and in particular deep learning models based upon artificial neural 
networks can draw upon diverse data that include clinical images and medical notes, as well 
as sensor-generated and genomic data. Such models can iteratively learn from large clinical 
databases and bring to bear the expertise of multiple medical specialties upon the data of 
individuals. Thus can medical decisions and personalized therapy for a single patient be 
informed by vast, collective experience [1]. 
 
Artificial intelligence (AI) methods and algorithms are being applied in varying ways across 
clinical and research domains. Yet machine learning (ML) has only begun to be applied to 
the menopausal transition. The end of a woman's fertility is a physiological state that is part 
of aging, and it is accompanied by a myriad of symptoms that include hot flashes, disrupted 
sleep, loss of energy, anxiety, and feelings of sadness and loss. These can transition to 
pathological phenomena such as incremental bone loss, diabetes, and cardiovascular 
disease and mortality. The complexity of menopause challenges general practitioners, 
gynaecologists, and women’s health practitioners to provide comprehensive care [2]. 
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By affording the analysis of very large amounts of clinical data, AI could improve the 
performance of diagnostic and prognostic models for the identification of health issues 
related to menopause and women at risk of developing complications, and assist physicians 
in the management of symptoms and health outcomes. ML could have a great impact upon 
the burden menopause places on health systems, the economy, and society. Although the 
implementation of AI is in an early phase, conditions such as osteoporosis that are 
prominent during and after menopause are being approached with deep learning (DL) 
models. Several studies have used a variety of neural network architectures using advanced 
algorithms and input parameters to identify groups at risk for osteoporosis, and positive 
results have been obtained with sensitivity values between 81 and 91% [2]. Image 
identification and recognition has also improved through the combination of bone density 
indicators and several texture parameters by models using feed forward neuronal networks, 
probabilistic neural networks, learning vectors quantification, and support vector machines 
(SVMs), which could potentially automate the diagnosis of osteoporosis and risk of fracture 
[2]. 
 
Machine learning also has shown promising results diagnosing menopause symptoms. In 
thirty-one women with hot flashes, applying SVMs improved the performance of sternal 
skin conductance in detecting hot flashes with a sensitivity of 87% and specificity of 97% [3]. 
The use of artificial neural networks for the screening of endometrial cancer in 
postmenopausal women achieved a sensitivity of 86% and specificity of 83% [4]. By bringing 
together clinical, genetic, and lifestyle data, AI can also improve personalized treatment in 
menopause. Barack et al., developed a computerized hybrid decision-making system to 
assist physicians by combining a clustering algorithm with knowledge-based algorithms to 
recommend hormone therapy for peri- and postmenopausal women [5]. 
 
Limited use has been made of AI in the study of cardiovascular risk factors of menopausal 
women that affect long-term health, survival, and quality of life. Šabanović et al., combined 
methods that included data mining and decision model trees in the analysis of clinical data 
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to evaluate and revise the standard definition of metabolic syndrome and the recognition of 
high cardiovascular risk among women who have hypertension and metabolic syndrome [6]. 
Gorodeski et al., implemented a random survival forest model to analyse 
electrocardiograms (ECGs) and all-cause mortality in 33,144 postmenopausal women and 
identified 20 variables that independently predict long-term mortality, 14 of which were 
ECG biomarkers [7]. 
 
Even though there has been progress in the application of AI to the study of women’s health 
during and after the menopausal transition, there is not yet evidence of its application in 
clinical practice. Translating AI to clinical care will require two lines of development. First, 
our understanding, identification, and measurement of mechanisms underlying menopausal 
metabolic traits must advance to get optimal input datasets. Second, robust algorithms and 
systems are needed along with access to larger datasets within an ethical framework that 
guarantees privacy and data protection. This has special importance for the application of 
DL models, which allow extraction of features and patterns that expose underlying, relevant 
characteristics through training with a large amount of data.  
 
We close with a cautionary note. AI is far from being perfected, and even the most 
sophisticated ML methods will be only as good as the data upon which they are trained. And 
in women’s health, high quality clinical data that include detailed information on all life 
stages and women's diversity and outcomes are essential. At the same time, research must 
be cautious with the introduction of historical data because algorithms can readily learn 
what health professionals do, which includes their mistakes, and they just as easily can 
incorporate biases induced by health systems inefficiencies [1]. Despite their empirical 
capabilities, ML models can be inexplicit and difficult to relate to existing biological and 
medical knowledge [8]. Therefore, it is important to understand that AI algorithms can assist 
and facilitate the work of health professionals and make them better, but cannot replace 
them. These limitations should be carefully studied and understood to ensure that the 
promise of artificial intelligence is adequately developed and used to help bridge the gap 
from usual care to precise care and personalised prevention and treatment.  
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